SCHEMBL14875587

SCHEMBL14875587

Cc1ccc(Cn2nc3c(=O)n(C4CCCCC4O)nc-3c3cccc(Cl)c32)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.44
CHRM1 P11229 3/20 0.44
CYP2C9 P11712 2/20 0.44
ALOX5 P09917 1/20 0.44
ESR1 P03372 5/20 0.40
AURKA O14965 2/20 0.34
AURKB Q96GD4 2/20 0.34
PDE4B Q07343 2/20 0.33
PDE4D Q08499 2/20 0.33
CCR9 P51686 1/20 0.33
TNF P01375 1/20 0.33
LITAF Q99732 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14884895 1.00 KCNH2 (0.44) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL7909764 1.00 KCNH2 (0.44) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL14875586 1.00 KCNH2 (0.44) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL14888022 1.00 KCNH2 (0.44) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL14875335 0.94 CHRM1 (0.40) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL7909734 0.94 CHRM1 (0.40) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL15107479 0.94 CHRM1 (0.40) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL15108042 0.94 CHRM1 (0.40) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL7908271 0.94 ESR1 (0.42) KCNH2CHRM1CYP2C9ALOX5ESR1
SCHEMBL15108055 0.94 ESR1 (0.42) KCNH2CHRM1CYP2C9ALOX5ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2398324-B1 PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2014-09-03 EP claimed
US-8653079-B2 Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2014-02-18 US claimed
US-20130102599-A1 PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2013-04-25 US claimed
US-20110301167-A1 PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2011-12-08 US claimed
EP-2398324-B1 PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2014-09-03 EP disclosed
US-8653079-B2 Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2014-02-18 US disclosed
US-8486946-B2 Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2013-07-16 US disclosed
US-20130102599-A1 PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2013-04-25 US disclosed
US-20110301167-A1 PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2011-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301167-A1 PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, CNR1, MTNR1A KCNH2 894/4885CHRM1 1/4885CYP2C9 1258/4885
US-20130102599-A1 PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, CNR1, MTNR1A KCNH2 894/4885CHRM1 1/4885CYP2C9 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.